Abstract:Shaan Lalvani, Rebecca M Brown Department of Neurology, The Mount Sinai Hospital, New York, NY, USA Correspondence: Rebecca M Brown, MD, PhD, The Mount Sinai Hospital, Department of Neurology, 1216 5th Avenue, New York, NY, 10029, USA, Tel +1 2128248579, Email Neurofibromatosis Type I (NF1) is a complex genetic condition that affects multiple organ systems and presents a unique set of challenges for clinicians in its management. NF1 is a tumor predisposition syndrome that primarily affect the peripheral and central nervous systems via the impact of haploinsufficiency upon neural crest lineage cells including Schwann cells, melanocytes, fibroblasts, etc. NF1 can further lead to pathology of the skin, bones, visual system, and cardiovascular system, all of which can drastically reduce a patient's quality of life (QOL). This review provides a comprehensive examination of the many specialties required for the care of patients with Neurofibromatosis Type 1 (NF1). We delve into the pathogenesis and clinical presentation of NF1, highlighting its diverse manifestations and the challenges they pose in management. The review underscores the importance of a multidisciplinary approach to NF1, emphasizing how such an approach can significantly improve patient outcomes and overall QOL. Central to this approach is the role of the NF expert, who guides a multidisciplinary team (MDT) comprising healthcare professionals from many areas of expertise. The MDT collaboratively addresses the multifaceted needs of NF1 patients, ensuring comprehensive and personalized care. This review highlights the need for further investigation to optimize the workflow for NF1 patients in an MDT setting, and to improve implementation and efficacy. Keywords: multisystemic, multidisciplinary team, quality of life, neurofibromatosis, NF expert, NF1, tumor predisposition syndrome Neurofibromatosis Type I (NF1) is a tumor predisposition syndrome characterized by a genetic mutation in the NF1 gene that affects the growth and regulation of the nervous system. Haploinsufficiency (50% decrease of functional protein) of the NF1 gene product neurofibromin is due to loss of function of one allele. The result is an increase in the proliferation rate, autocrine and paracrine signaling, and inflammatory cell signaling of Schwann cell precursors in the neural crest population. 1 NF1 has the propensity to manifest in multiple organ systems, providing a just rationale for multidisciplinary management. The loss of one NF1 allele in all tissues of the body results in multi-system abnormalities that can immensely complicate a patient's treatment plan and greatly impact outcome measures. 2 This review will delve into the pathogenesis and clinical presentation of NF1, in addition to closely examining how a multidisciplinary approach can benefit outcomes and quality of life (QOL). Figure 1 Venn diagram that illustrates the NF expert's role in a Multidisciplinary NF1 Care Team. Figure 2 Schematic outlining the necessary specialties to be included when dealing with specific clinical manifestations of NF1. *For optimal management, it is advisable to consult with a NF expert for all these conditions, prior to referral to specialties included above. **Neurosurgery should be considered imperative when addressing skeletal malformations involving the spine. NF1 is the most common of the peripheral nerve tumor genetic syndromes, which also includes schwannomatosis and NF2-related schwannomatosis. Its incidence is approximately 1 in 3000 live births. The condition stems from a heterozygous mutation in the NF1 gene on Chromosome 17q11.2 that occurs during gametogenesis. The NF1 gene encodes the protein known as neurofibromin, a known tumor suppressor which inhibits the GDPase-activating domain (GAP) of the intracellular signaling protein Ras (rat sarcoma). Ras resides within a family of GTPases that is involved in promoting cellular proliferation. Loss of the wild type NF1 allele during propagation of cells in the Schwann lineage directly causes the growth of peripheral nerve sheath tumors and is the only mutation typically identified. 3 With regard to clinical presentation, the most apparent features of NF1 include cutaneous neurofibromas (CN) purportedly arising from small nerves of the skin, and plexiform neurofibromas (PN) that derive from Schwann cells supporting large peripheral nerves and can invest in multiple bundles of nerves (nerve plexi). The diagnostic criteria of NF1 (Table 1), were updated in 2021. NF1 patients are susceptible to both benign and malignant nerve sheath tumors, 4 as well as neurocognitive and developmental deficits, mood disorder, osseous lesions including dystrophic scoliosis and pseudoarthrosis, neuroendocrine tumors, breast cancer, and others. 2 T -Abstract Truncated-

Family Reflections: Neurofibromatosis and our family perspective

Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas

Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

Translating current basic research into future therapies for neurofibromatosis type 1

Clinical manifestations of neurofibromatosis type 1 – a diagnostic and management challenge

NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies

Reproductive decision‐making experiences of Australian adults with neurofibromatosis type 1 and schwannomatosis

A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials

Neuropsychiatric Manifestations, Reduced Self-Esteem and Poor Quality of Life in Children and Adolescents with Neurofibromatosis Type 1 (NF1): The Impact of Symptom Visibility and Bullying Behavior

Clinical Challenges and Therapeutic Management

Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility

[Treatment of emotion regulation problems in people with neurofibromatosis type 1]

Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study

Satisfaction from surgical treatment and its influence on the wellbeing of patients with Recklinghausen disease - preliminary report

Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach

Therapeutic advances in treatment of patients with neurofibromatosis type 1 and type 2

[Progress in neurosurgical treatment of neurofibromatosis type 1]

Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review

Plexiform Neurofibroma: A Case Report

Health Supervision for Children With Neurofibromatosis Type 1

Establishing priorities in neurofibromatosis research: A workshop summary